CanSino Biologics Inc. (6185) announced approval from the National Medical Products Administration of China (NMPA) to extend the applicable age range of its Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197), known commercially as Menhycia®, from “children aged 3 months to 3 years old (47 months)” to “children aged 3 months to 6 years old (83 months).”

Menhycia® is the first MCV4 vaccine in China, addressing an unmet demand for a high-end meningococcal vaccine and narrowing the gap between the domestic and international markets. The announcement highlights strong market performance and continued expansion of Menhycia®’s market share. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.